Unpicking the combination lock for mutant BRAF and RAS melanomas

Cancer Discov. 2013 Jan;3(1):14-9. doi: 10.1158/2159-8290.CD-12-0520.

Abstract

Large-scale, unbiased combinatorial drug screening has been used to identify effective genotype-selective therapeutic combinations that show promising activity in preclinical models of mutant BRAF andRAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Humans
  • Melanoma / drug therapy*
  • Proto-Oncogene Proteins B-raf / genetics*
  • ras Proteins / genetics*

Substances

  • Antineoplastic Agents
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • ras Proteins